Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience

Journal of Personalized Medicine

Benjamín Garcia-Bloj¹  Patricio Manque¹  Marcelo Garrido¹  Juvenal A. Ríos¹  María Paz Rodríguez Z.¹  Alejandro Berkovits¹  André Fassler²  Jorge Gallardo³  Mauricio P. Pinto⁴  Miguel Cordova-Delgado⁴  Laura Itriago⁵  Alejandro Majlis⁵  Carlos Regonesi⁵  José Miguel Reyes⁵  Luis Cereceda⁵  Mauricio Mahave⁶  María Elisa León⁷  Pablo Rodríguez⁸ 

[1] Centro de Oncologia de Precision, Escuela de Medicina, Universidad mayor, Santiago 7560908, Chile;Clínica Dávila, Santiago 8420384, Chile;Clínica Indisa, Santiago 7520440, Chile;Department of Hematology and Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330032, Chile;Division of Medical Oncology, Clínica Las Condes, Santiago 7591047, Chile;Fundación Arturo Lopez Perez, Santiago 7500855, Chile;Medical Oncology, Clínica Reñaca, Viña Del Mar 2540364, Chile;Oncology Department, Clínica IRAM, GESMED, Santiago 7630370, Chile;

关键词: precision oncology;    Next-Generation Sequencing;    on-label;    off-label;    therapy;   

DOI  :  10.3390/jpm12020195

来源: DOAJ

【 摘 要 】

Major advances in sequencing technologies and targeted therapies have accelerated the incorporation of oncology into the era of precision medicine and “biomarker-driven” treatments. However, the impact of this approach on the everyday clinic has yet to be determined. Most precision oncology reports are based on developed countries and usually involve metastatic, hard-to-treat or incurable cancer patients. Moreover, in many cases race and ethnicity in these studies is commonly unreported and real-world evidence in this topic is scarce. Herein, we report data from a total of 202 Chilean advanced stage refractory cancer patients. Retrospectively, we collected patient data from NGS tests and IHC in order to determine the proportion of patients that would benefit from targeted treatments. Overall >20 tumor types were included in our cohort and 37% of patients (n = 74) displayed potentially actionable alterations, including on-label, off-label and immune checkpoint inhibitor recommendations. Our findings were in-line with previous reports such as the cancer genome atlas (TCGA). To our knowledge, this is the first report of its kind in Latin America delivering real-world evidence to estimate the percentage of refractory tumor patients that might benefit from precision oncology. Although this approach is still in its infancy in Chile, we strongly encourage the implementation of mutational tumor boards in our country in order to provide more therapeutic options for advanced stage refractory patients.

【 授权许可】

Unknown